Aktis Oncology, Inc. AKTS 深 沪
等待开盘 07-01 09:30:00 美东时间
32.23
+2.120
+7.04%
华盛通- 最 高34.1899
- 今 开29.63
- 成交量 121.20万股
- 最 低 29.49
- 昨 收 30.11
- 总市值 17.82亿
- 52周最高 34.1899
- 市盈率 静 --
- 换手率 2.19%
- 52周最低 14.72
- 委 比 -99.55%
- 总股本 5527.74万
- 历史最高 34.1899
- 量 比 1.73
- 振 幅 15.61%
- 历史最低 14.72
- 每 手 1
- 风险率 2.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BNP Paribas analyst Colin Liu initiated coverage on PDD Holdings Inc – ADR (NASDAQ:PDD) with an U...
06-16 19:15
Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index gaining over 100 points on Friday. Shares of Rezolve AI PLC (NASDAQ:RZLV) rose sharply after the company announced its board of directors will seek shareholder approval at its June 30 annual general meeting for a capital reduction and a $300 million s...
06-12 22:09
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35
HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy and raises the price target from $33 to $35.
06-03 01:00
Aktis Oncology's AKY-2519 Shows Robust Tumor Uptake And Favorable Dosimetry Across Solid Tumors In First-In-Human B7-H3 Radiopharmaceutical Data Presented At ASCO 2026
Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic
05-22 05:22
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
Aktis Oncology reported positive first-in-human clinical imaging and dosimetry data for AKY-2519, a B7-H3-targeted radiopharmaceutical, demonstrating robust tumor uptake and limited normal tissue exposure. The data, to be presented at the 2026 ASCO Annual Meeting, suggest AKY-2519 may offer a differentiated profile compared to approved radiopharmaceuticals, particularly in salivary gland sparing. Aktis plans to initiate a second Phase 1b trial in...
05-21 21:21
Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate
Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.64 percent. This is a 97.96 percent increase over losses of $(18.60) per share from
05-12 05:35
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Aktis Oncology reported Q1 2026 financial results and business highlights, advancing its clinical-stage radiopharmaceuticals AKY-2519 and AKY-1189. AKY-2519, targeting B7-H3 expressing tumors, initiated a Phase 1b trial in metastatic castration-resistant prostate cancer (mCRPC) with preliminary data expected in 2027. The company also plans a basket trial for additional solid tumors later this year. AKY-1189, targeting Nectin-4, received FDA Fast ...
05-11 20:01
William Blair Initiates Coverage On Aktis Oncology with Outperform Rating
William Blair analyst Alexandra Ramsey initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating.
04-29 21:32
